ADIAOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Adia Med, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.13−0.01 (-7.14%)
Close on Oct 19, 2026
- Market cap
- $20.98M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.0884 (+212.5%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Adia Med, Inc. grew revenue 10879.7% to $700.51K over fiscal 2025. Free cash flow was -$192.43K.
Revenue
$700.51K
+10879.7% vs. a year earlier
Operating income
-$366.49K
FY2025
Free cash flow
-$192.43K
FY2025
EPS, diluted
$0.00
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $20.98M
- P/E ratio
- –
- Price to sales
- 29.95
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -0.92%
Fundamentals
- Revenue
- $700.51K
- Net income
- -$395.46K
- EPS, diluted
- $0.00
- Free cash flow
- -$192.43K
- Book value per share
- -$0.00
- Diluted shares
- 161M
Three years at a glance
Fiscal years 2023 to 2025, USD
Revenue
$700.51K+10879.7% YoY
Gross profit
$191.67K+8636.1% YoY
Operating income
-$366.49K
Net income
-$395.46K
EPS, diluted
$0.00
Free cash flow
-$192.43K
Reported period